ABL Bio Inc.

ABL Bio announces clinical collaboration to evaluate ABL103 in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors. The full press release can be found through the link: https://lnkd.in/gydB-Q-4

ABL Bio was selected as the 'Most Promising Biologics Drug' development company at the Korea Biopharma Excellence Awards 2024 hosted by IMAPAC. We are very happy to recieve the award, and believe that this is good opportunity to promote our technology for developing bispecific antibodies and ADC pipeline. Thank you for everyone and ABL Bio will keep focusing on the development of bispecific antibodies and bispecific ADCs.

ABL Bio today announced that ABL503 (ragistomig) patent has been issued in Indonesia and China. ABL503 is being jointly developed with ABL’s global partner I-Mab. ABL503 is a bispecific antibody that simultaneously targets PD-L1, an immune checkpoint protein, and 4-1BB, which is involved in immune T cell activation. Promising Phase 1 data were presented at the American Society for Clinical Oncology Annual Meeting (ASCO 2024). Securing the patents for ABL503 in various countries around the world marks an important milestone for the Company.

ABL Bio gets a U.S. patent for the ROR1 monoclonal antibody. This was used for ROR1 ADC ABL202 jointly developed by ABL Bio and RigaChem Bio. ABL202 was licensed out to Cstone in October 2020. ABL Bio plans to acclerate the development of bispecific ADCs by leveraging its ABL202 development experience and bispecific antibody expertise. ABL Bio aims to submit INDs for at least three bispecific ADCs in 2025. Please pay attention to ABL Bio, which dreams of growing into a global biotech company.

ABL Bio participated in the World ADC Asia 2024 and presented its bispecific ADC development strategy. The title of the presentation is ‘Exploring the Advantages of Using Bispecific ADCs & Their impact on in vitro activities and toxicity’. ABL Bio is focusing on developing next-generation bispecific ADCs. As most bispecific ADCs are in the early clinical development stage, ABL Bio anticipates that it will be able to take a global leadership through rapid market entry.

에이비엘바이오가 7월 3일(수) 오전 8시 40분 유튜브를 통해 온라인 간담회를 개최합니다. 이번 간담회에서는 에이비엘바이오의 차세대 이중항체 ADC 개발 전략과 올해 ASCO에서 공유된 ABL503 및 ABL202의 임상 1상 중간 데이터가 소개될 예정입니다. 많은 관심과 시청 부탁 드립니다! 유튜브 링크: https://lnkd.in/gpc2u2JU

ABL Bio and KAIST announced the publication of non-clinical studies of ABL503 (ragistomig) in ‘Clinical Cancer Research’, an internationally recognized journal of the American Association for Cancer Research. ABL503 is a bispecific antibody that is being jointly developed by ABL Bio and its global partner I-Mab Biopharma using ABL Bio’s 4-1BB-based bispecific antibody platform ‘Grabody-T’. The researchers explained that ABL503 may improve the anticancer effect of PD-1 inhibitor by enhancing the function of exhausted CD8+ T cells and inducing tumor growth inhibition. You can find the paper at: https://lnkd.in/gTHxcVZx

Our global partner Compass Therapeutics published a trial in progress paper on ABL001 (CTX-009) in the international journal ‘Future Oncology’. This paper contains information on the research methodology, including study goals, clinical design and primary endpoints of COMPANION-002, a Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen. If you want to get more information about COMPANION-002, please see this paper: https://lnkd.in/exMdsUpQ

ABL Bio’s Partner, I-Mab announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb. The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by ABL Bio and I-Mab, with Bristol Myers Squibb’s immune checkpoint inhibitor, nivolumab, and chemotherapy (FOLFOX or CAPOX), as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. https://lnkd.in/gA6wfXQZ

ABL Bio successfully completed its poster presentation on the interim Phase 1 clinical data of ABL503 (TJ-L14B, ragistomig) at the ASCO 2024. ABL503 is a bispecific antibody being jointly developed by ABL Bio and its global partner I-Mab Biopharma, using ABL Bio’s 4-1BB-based bispecific antibody platform ‘Grabody-T’. According to the poster, among the 44 efficacy-evaluable patients, one complete response (CR) and six partial responses (PRs) were observed. Five of these patients did not respond to prior PD-(L)1 inhibitor treatment or experienced cancer recurrence after PD-(L)1 treatment. ABL Bio plans to consider future clinical strategies by comprehensively understanding these interim data and additional results confirmed in the ongoing Phase 1 clinical trial.